Cizzle Bio and BioBridge Global Partner to Enhance Lung Cancer Detection in South Texas

Cizzle Bio and BioBridge Global Collaborate for Early Lung Cancer Detection

In a groundbreaking move towards enhancing early lung cancer detection, Cizzle Bio, Inc. has formed a strategic partnership with BioBridge Global, a prominent healthcare services organization based in San Antonio, Texas. This collaboration aims to extend the availability of Cizzle Bio's advanced CIZ1B Biomarker Blood Test, designed specifically for lung cancer, to licensed healthcare providers across South Texas.

The collaboration, which reflects Cizzle Bio’s ongoing commitment to improve patient outcomes, will see BBG Advanced Therapies, a subsidiary of BioBridge Global, serve as a CLIA-certified laboratory partner for the CIZ1B test. This partnership is crucial as it ensures that the test meets stringent quality standards and undergoes necessary validation processes, which will allow healthcare providers in the region to offer it to their patients.

The Importance of Early Detection

Lung cancer continues to pose one of the greatest threats as it remains the leading cause of cancer-related deaths globally. One of the significant hurdles in combatting this disease has been the late-stage diagnosis faced by many patients. The CIZ1B Biomarker Blood Test offers a minimally invasive solution to this issue, aiming to enhance early detection so that patients can be diagnosed and treated at a stage when their options are more favorable.

With the CIZ1B test demonstrating impressive clinical performance—boasting 95% sensitivity and a 96% negative predictive value for Stage I detection—this collaboration positions South Texas at the forefront of early cancer diagnostics. Bill Behnke, the founder and CEO of Cizzle Bio, emphasized the necessity of making innovative healthcare solutions accessible to patients. He stated, "Early detection can dramatically improve outcomes, yet too many patients are diagnosed after lung cancer has progressed."

A Commitment to Community Health

This collaboration not only marks an advancement in technology but also signifies a substantial commitment to addressing health disparities prevalent in South Texas. Adrienne Mendoza, COO of BioBridge Global, echoed this sentiment, asserting that true innovation comes when patients have access to life-saving technologies. She stated, "This collaboration reflects BBG's commitment to working alongside pioneering organizations like Cizzle Bio to help translate scientific advances into real-world healthcare solutions."

Both companies recognize the critical role of providing healthcare practitioners with reliable, high-quality tests that they can trust to recommend to their patients. Marty Landon, CEO of BioBridge Global, highlighted the synergies brought about by merging their innovative biomarker technology with BBG's expertise. This comprehensive partnership aims not only to expand access to advanced cancer screening but also to foster confidence in the reliability of the tests available to healthcare professionals.

Looking Ahead

The partnership between Cizzle Bio and BioBridge Global stands as a beacon of hope in the ongoing battle against cancer. This initiative forms part of Cizzle Bio's broader national strategy to establish a robust network of laboratory partners. By expanding access to advanced diagnostic tools like the CIZ1B Biomarker Blood Test, Cizzle Bio and BioBridge Global reaffirm their shared mission to empower patients, equip healthcare providers, and ultimately improve outcomes across communities.

As the test becomes available, the potential for early detection will undoubtedly save lives and transform the way lung cancer is diagnosed and treated. Cizzle Bio and BioBridge Global are excited about this collaboration and are eager to make a meaningful impact in the lives of patients facing lung cancer.

For more information on Cizzle Bio and their innovative diagnostic technologies, visit CizzleBio.com. For details regarding BioBridge Global and their services, check out BioBridgeGlobal.org.